Participants Sought for Microbiome ALS Trial
Researchers are looking for people with ALS and healthy volunteers to participate in the Microbiome Assessment in People with ALS (MAP ALS) study.
Author: Amy Madsen
CReATe Consortium’s Phenotype, Genotype & Biomarkers in ALS and Related Disorders (PGB) Study Seeks Participants
Researchers are looking for people to participate in CReATe Consortium’s PGB study to help learn about ALS and related diseases.
Trial to Study Home-Based ALS Testing Seeks Participants
Researchers are looking for 220 people with ALS and 30 people who do not have ALS from around the country to participate in the ALS At HOME study.
ReveraGen BioPharma’s DMD Drug Vamorolone Gets FDA Fast Track Designation
Vamorolone (formerly VBP15), under development by ReveraGen BioPharma, has received FDA Fast Track designation for the treatment of DMD.
FDA Gives Akashi Green Light to Resume Clinical Development of DMD Drug HT-100
Akashi Therapeutics announced that the FDA has cleared the way for the company to resume clinical development of HT-100 in boys with DMD.
A Deep Dive into the Science of Neuromuscular Diseases: MDA’s Scientific Conference Brings Researchers Together to Share Ideas, Talk Shop
Over 500 of the sharpest minds in research have gathered at MDA’s Scientific Conference as they work to unlock the secrets of neuromuscular diseases.
Participants Sought to Test Beetroot Juice in BMD
Researchers are looking for people to participate in a clinical trial, sponsored by Cedars-Sinai Medical Center, to test the safety and efficacy of beetroot juice extract in people with BMD.
NP001 ALS Trial Seeks Participants
Researchers are looking for people to participate in a phase 2 clinical trial, sponsored by Neuraltus Pharmaceuticals, that is designed to test whether the investigational drug NP001 slows progression of signs and symptoms in ALS.
New Research, Supported by MDA and the CMT Association, Examines Gene Therapy in CMT
New research, supported by MDA and the CMT Association, examines gene therapy in CMT.
FDA Will Review Soliris for Myasthenia Gravis
Alexion Pharma announced the FDA will review its investigational drug eculizumab (brand name Soliris) for treatment of refractory generalized MG.
